Galera Therapeutics and Obsidian Therapeutics have announced a definitive merger agreement in an all-stock transaction, a move bolstered by a concurrent $350 million private placement. This strategic combination will take the privately-held Obsidian public, allowing it to advance its pipeline of novel engineered tumor-infiltrating lymphocyte (TIL) cell therapies. The newly formed entity will operate under the name Obsidian Therapeutics and aims to trade on Nasdaq under the ticker symbol "OBX."
A Strategic Path to Public Markets
This reverse merger provides a crucial pathway for Obsidian to access public capital markets, following Galera's extensive search for strategic alternatives after facing regulatory setbacks. The combined company will be led by Obsidian's current Chief Executive Officer, Madan Jagasia, M.D., ensuring continuity in its scientific and clinical direction. Upon closing, pre-merger Obsidian stockholders will own approximately 53.2% of the new entity, with private placement investors holding 45.0% and Galera stockholders retaining about 1.8%.
Advancing a Novel TIL Cell Therapy
The primary focus for the new company will be its lead product candidate, OBX-115, a genetically engineered autologous TIL cell therapy. This innovative treatment is currently being evaluated in a Phase 2 clinical trial for advanced melanoma and a Phase 1 study for non-small cell lung cancer (NSCLC). OBX-115 leverages Obsidian’s proprietary cytoDRIVE™ platform to regulate membrane-bound IL15, which is designed to enhance TIL persistence and eliminate the need for toxic IL2 infusions.
Significant Financial Backing
The transaction is supported by an oversubscribed $350 million private placement, signaling robust confidence from a syndicate of new and existing life sciences investors. Participants include Balyasny Asset Management, RA Capital Management, and Atlas Venture, among other leading firms. This substantial capital injection is expected to fund the combined company’s operations into the second half of 2028, providing a clear financial runway through multiple key milestones.
Key Clinical Milestones on the Horizon
The secured funding provides capital through several critical clinical data milestones anticipated for OBX-115 in 2027. The company expects to report Phase 1 data from its ongoing NSCLC trial in the first half of the year. By the end of 2027, Obsidian plans to release topline, registration-enabling data from its melanoma trial, a pivotal event for the therapy's development path.
Future for Galera's Assets and Shareholders
While the new entity will prioritize Obsidian's pipeline, it will also continue to support Galera's programs, including a pan-NOS inhibitor for advanced breast cancer. Galera stockholders will retain a contingent value right for 95% of all future milestones from a prior asset purchase agreement with Biossil.ai. This arrangement offers potential future value for Galera's investors following the company's decision to halt its own clinical activities.
The merger between Obsidian and Galera Therapeutics represents a significant strategic realignment, creating a well-capitalized public company focused on pioneering TIL cell therapies. With a strong leadership team, a promising lead candidate in OBX-115, and a clear path to key clinical readouts, the new Obsidian is positioned to make meaningful progress. This transaction ultimately aims to accelerate the development of potentially transformative treatments for patients battling difficult-to-treat solid tumors.